GlassScriptPhysician profile
Vernon Brewer
NPI 1558524199
$1,343.48
in general payments reported to CMS, 2019-2025
22 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.29 · 2024: $321 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.48 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.72 | 2025 | |
| Jazz Pharmaceuticals INC. | $141.57 | 2025 | |
| Csl Behring | $102.55 | 2025 | Andembry, Haegarda |
| Exact Sciences Corporation | $75.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $73.08 | 2025 | Mounjaro, Zepbound, Kisunla |
| Sanofi-Aventis U.S. LLC | $71.52 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $64.38 | 2024-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $61.95 | 2024-2025 | |
| Novo Nordisk INC | $61.65 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $39.19 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $35.93 | 2024-2025 | Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.63 | 2025 | Caplyta |
| Amgen INC. | $31.38 | 2024 | Repatha, Otezla |
| Dexcom, INC. | $30.75 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $26.69 | 2024 | Tymlos |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $23.14 | 2025 | |
| Inspire Medical Systems, INC. | $21.17 | 2024 | Inspire |
| Phathom Pharmaceuticals, INC. | $18.32 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $18.28 | 2025 | Gemtesa |
| Insulet Corporation | $17.19 | 2025 | Omnipod |
| Teva Pharmaceuticals USA, INC. | $16.08 | 2025 | Uzedy |
| Novartis Pharmaceuticals Corporation | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.